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ABSTRACT  Imatinib (IM) is a tyrosine kinase inhibitor that blocks the kinase activity of 
BCR-ABL fusion protein, thereby inhibiting Ph-positive leukemic progenitor cell proliferation. 
Imatinib has produced excellent clinical and cytogenetic/molecular responses against chronic 
myelogeneous leukemia (CML), and is now the first-line treatment of CML. A few to 34% of 
patients reaches a complete molecular response (CMR) by IM treatment, however it is not 
known whether patients who have a CMR require continued therapy to maintain it or whether IM 
can safely be discontinued. We analyzed the cytogenetic and molecular outcomes of 7 patients 
with CML, for whom IM therapy had been discontinued after a CMR. From January 2002 to 
September 2006, 16 patients reached CMR by IM therapy at our institute. Because of economic 
reasons or adverse events, 7 of the 16 patients had IM discontinued and all had an early 
relapse. The median time to relapse was 4.9 months (range, 2-6 months). One factor for relapse 
was that the duration of molecular remission before IM was discontinued was short (4.3 months; 
range,1-12 months). Based on these results, discontinuation of IM therapy for patients who 
have a CMR can not be recommended. More information about cases of Japanese CML must 
be gathered in order to devise effective CML treatment strategies for patients who achieved a 
CMR.
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INTRODUCTION
   Chronic myelogenous leukemia (CML) is a 
myeloproliferative neoplasm characterized by 
the presence of the bcr-abl fusion gene due to 
reciprocal translocation between chromosomes 9 
and 22. It is visible cytogenetically as a shortened 
chromosome 22 (Philadelphia [Ph] chromosome)1,2）. 
The molecular consequence of this translocation 
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is the novel fusion gene, bcr-abl, which encodes a 
constitutively active protein tyrosine kinase3）. The 
resulting BCR-ABL fusion protein confers enhanced 
proliferative activity and decreased sensitivity 
to apoptotic cell death in CML cells. A tyrosine 
kinase inhibitor, imatinib (IM) was designed to bind 
specifically to the adenosine triphosphate (ATP)-
binding site of the tyrosine kinase protein which 
causes Ph-positive leukemia4）. It has high, relatively 
specific, biochemical activity and an acceptable 
pharmacokinetic and toxicity profile, and has been 
rapidly introduced into clinical practice4－8）. IM has 
produced encouraging results in all CML phases4,9
－11）. This has resulted in a revolutionary advance in 
the management of CML and, by extension, a shift 
in the paradigm for cancer management in general. 
   It has had excellent clinical and cytogenetic/
molecular effects in Japanese CML patients9,10,12－15）. 
For IM-treated patients newly diagnosed with CML, 
the complete hematologic response (CHR) rate after 
5 years was 98%, the complete cytogenetic response 
(CCR) rate 92%, and the major molecular response 
(MMR) rate 87%10）. In addition to having a CCR, a 
few to 34% of the patients had a complete molecular 
response (CMR), defined as an undetectable level 
of bcr-abl transcripts as measured by a quantitative 
or qualitative polymerase chain reaction (PCR)16,17）. 
However, it is not known if continued therapy is 
necessary to maintain this level of response or if IM 
can be safely discontinued. 
   We analyzed the cytogenetic and molecular 
outcomes of 7 patients with CML, for whom IM 
therapy had been discontinued after having a bone 
marrow CMR. 
PATIENTS AND METHODS
Patients
   Statuses of consecutive patients at our institute 
who had a confirmed diagnosis of Ph-positive 
CML, were analyzed. Patients were followed from 
January 2002 to September 2006, 19 with CML 
being treated with IM. Two of them had accelerated 
phase(AP)-CML, 17 chronic phase(CP)-CML. The 
19 included 10 patients who received IM after failed 
IFN α therapy and 9 who received IM as the first 
line of therapy for CML. A CCR occurred in 17 
(89.5% of the 19 patients treated), and 16 (84.2% of 
those treated) had undetectable bcr-abl transcripts 
in at least one nested-PCR analysis (i.e., CMR). Of 
these, 7 who had a CMR had IM discontinued.
   We analyzed their cytogenetic and molecular 
outcomes. Imatinib was discontinued because 
of economic reasons or adverse events. IM was 
discontinued with the patients' informed consent 
and monitoring of their cytogenetic and molecular 
outcomes was continued.
Evaluation and criteria for cytogenetic responses
   Patients'  hematological, cytogenetic, and 
molecular responses were evaluated. Bone marrow 
cells underwent cytogenetic analysis by the 
G-banding technique and fluorescence-in-situ-
hybridization (FISH). For chromosome analysis, 20 
mitotic cells in metaphase and 1,000 interphase cells 
were analyzed by FISH.
   A CCR was defined as the absence of Ph-positive 
metaphases or as being below the detection limit of 
a bcr-abl signal by FISH analysis. 
Evaluation and criteria for molecular responses
   Bone marrow cells underwent molecular analysis 
by an RT-nested PCR. Total cellular RNA was 
extracted from mononuclear bone marrow cells 
with SepaGene RV-R(Sankojyunyaku). The reverse 
transcription reaction was run with up to 1μg of 
total RNA in an RT mixture [5×RT buffer, 2.5mM 
dNTP, reverse primer, 100mM DTT, RNassin 
(40U/μl), M-MLV RTase (200U/μl)], at 37℃ for 
60 minutes, then at 99℃ for 5 minutes, followed 
by cooling down to 20℃. The cDNA then was 
amplified by a nested PCR that used two sets of 
primers. 
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   The sequences of the 1st PCR primer pair were 
5’-GCTTCTCCCTGACATCCGTG-3’(forward) 
and 5’-GGCCCATGGTACCAGGAGTG-3’ 
(reverse), those of the 2nd PCR primer pair were 5’
-GGAGCTGCAGATGCTGACCAAC-3’(forward) 
and 5’-GTTTCTCCAGACTGTTGACTG -3’
(reverse). The first PCR which used cDNA with the 
1st PCR Mixture [DEPC-treated water, 10×PCR 
buffer, 2.5mM dNTP, forward and reverse primers, 
Taq polymerase(5U/μl)] was run using 35 cycles of 
94℃ for 30 seconds, 63℃ for 30 seconds, and 72℃ 
for 30 seconds. The second PCR was run on the 
1st PCR products and the 2nd PCR mixture [DEPC- 
treated water, 10×PCR buffer, 2.5mM dNTP, 
forward and reverse primers, Taq polymerase (5U/
μl)], for 35 cycles of : 94℃ for 30 seconds, 63℃ 
for 30 seconds, and 72℃ for 30 seconds.
   A CMR was defined as an undetectable level of 
bcr-abl transcripts confirmed by an RT-nested PCR. 
RESULTS
   From January 2002 to September 2006, 19 
patients in various stages of CML were treated with 
IM at our institute. The median follow-up time from 
start of treatment was 42.6 months (range, 10-56 
months). Seventeen (89.5%) had a CCR, and 16 
(84.2%) had at least one analysis showing a CMR 
(data not shown). The median time from start of 
treatment to a CCR was 5.6 months (range, 1-12 
months) and to a CMR 10.6 months (range, 4-37 
months). For 7 of the 16 patients who had a CMR 
IM was discontinued. Patients' characteristics and 
responses to IM therapy are summarized in Table 
1. Of those 7 patients, 6 had CP-CML and one AP-
CML. Median age was 55.3 years old (range, 31-73 
years old), and 5 were women. The median follow-
up period from the time treatment started was 50.3 
months (range, 30-56 months). It included 5 patients 
who received IM after IFN-α therapy failed, and 
Table 1.　Patients characteristics and responses to IM therapy
Patient Sex Age 
CML
status at
diagnosis
Previous
therapy
Time from
IM itiation
(months)
CML tatus
at IM
initiation
Best
response
to IM
Time to
CCR
(months)
Time to
CMR
(months)
Follow up
time
(months)
1 F 31 CP IFN 18 CP CMR 3 6 56
2 F 53 CP IFN 90 CP CMR 6 6 56
3 M 58 CP IFN 124 CP CMR 2 4 55
4 F 49 CP IFN 38 CP CMR 4 4 52
5 F 61 CP IFN 24 AP CMR 4 10 50
6 M 73 CP - 0 CP CMR 7 18 53
7 F 62 CP - 2 CP CMR 3 6 30
IM: imatinib mesylate   CML: chronic myelogenous leukemia  F: female  M: male  CP: chronic phase CML  AP: accelerated phase CML
IFN: interferon-alpha  CCR: complete cytogenetic response   CMR: complete molecular response(RT-nested PCR negative)
Table 2.　Outcomes of the 7 patients who discontinued IM therapy after having  molecular remission
Patient Sex Age Previous therapy
Number of IM
discontinu-ations
(Times)
Time from
CCR to IM
discontinuation
(Months)
Time from
CMR to IM
discontinuation
(Months)
Time to relapse
(Months)
Present 
status
Present 
IM dose
1 F 31 IFN 2 4/4 1/4 6(cy)/6(cy) CMR 400mg
2 F 53 IFN 3 1/nd/7 1/12/7 2(cy)/3(cy)/4(cy) CMR 400mg
3 M 58 IFN 1 5 1 3(cy) CMR 400mg
4 F 49 IFN 2 5/1 1/1 6(mol)/6(mol) CMR 100mg
5 F 61 IFN 1 26 7 6(cy) CMR 300mg
6 M 73 - 1 17 6 6(cy) CMR 400mg
7 F 62 - 1 9 6 6(cy) CMR 200mg
IM: imatinib mesylate   CML: chronic myelogenous leukemia  F: female  M: male  CP: chronic phase CML  AP: accelerated phase CML
IFN: interferon-alpha  CCR: complete cytogenetic response   CMR: complete molecular response(RT nested-PCR negative)  partial CR:
partial complete response  nd:  not done  cy: cytogenetic relapse  mol: molecular relapse
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2 who received IM as the first line of therapy for 
CML. The median period from diagnosis to IM 
initiation was 42.3 months (range, 0-124 months). 
Imatinib was started at 400mg/day for all the 
patients. The median period to CCR was 4.1 months 
(range, 2-7 months) and to CMR 7.7 months (range, 
4-18 months). The median duration of CMR status 
until IM discontinuation was 4.3 months (range, 
1-12 months).
   Totally, IM was discontinued 11 times for 7 
patients. All who had IM discontinued after gaining 
a CMR experienced early relapse. The median time 
to relapse was 4.9 months (range, 2 to 6 months). 
Their cytogenetic and molecular outcomes after 
stopping IM are summarized in Table 2. After 
discontinuation, one patient experienced molecular 
relapse (but not cytogenetic or hematologic ones). 
Cytogenetic relapses occurred in 6 patients after 2 
to 6 months.
   Imatinib therapy re-introduced for all 7 patients 
produced a new decline in the disease. Three had the 
IM dose reduced to 100mg-300mg/day because of 
adverse events. All of them reached CMR, and none 
acquired resistance to IM. It should be noted that 
one patient who received 100mg/day low dosage IM 
had a 3rd CMR (patient No.4). 
DISCUSSION
   The introduction of IM has revolutionized the 
treatment of CML in Japan. Imatinib has produced 
encouraging results for all phases of CML9－11）. 
Current studies have shown that a 75% to 90% of 
patients treated with IM who had early CP-CML 
had a CCR9,18,19）. In addition, up to 34% of patients 
studied had a CMR9,16,17）.
   These findings confirm the superiority of IM 
therapy to conventional drug therapy (IFN α with 
or without cytosine arabinoside) for patients with 
CML. Today in Japan IM is the standard therapy for 
patients with CML5,12）, but it is not known whether 
those who have a CMR, require continued therapy 
to maintain it or IM can be safely discontinued. At 
present this is the most important concern for CML 
management.
   Because the CCR frequency is very high in 
IM-treated patients, PCR monitoring of minimal 
residual disease has become more important. 
Currently, patients are routinely followed by means 
of quantitative or qualitative PCR techniques during 
therapy to determine bcr-abl transcript levels. About 
70% of CP-CML patients who had a CCR, were 
considered to have a major molecular response 
(MMR)17）. Complete and major molecular responses 
are associated with excellent prognoses due to IM 
therapy9,10,16,17,19,20）. The MMR incidence (about 30% 
to 70%) is reasonable but CMRs have been reported 
at lower frequencies of 7% to 10% for standard-dose 
IM given patients with newly diagnosed CML16,19）. 
Several updates have shown a higher frequency 
of CMR. Cortes et al17） reported that of 280 CP-
CML patients (117 after IFN failure, 163 previously 
untreated) who had had a CCR with IM, 174 (62%) 
also had an MMR, and 95 (34%) at least once had 
undetectable bcr-abl transcripts. Moreover, the 
median period from start of treatment for an MMR 
to occur was 10 months (range, 2.8-46 months) and 
for a CMR 16.7 months (range, 3-48 months)17）. 
Rosti et al21）reported 22 of 191 patients who had a 
CMR (12%) in late CP-CML who had been treated 
with IM after IFN-α failure (median follow-up 
time, 45 months). In Japan, Matsuo et al13）evaluated 
the cytogenetic and molecular effects of IM in 
a practical setting in Nagasaki Prefecture. In his 
group I, consisting of patients with newly diagnosed 
CML (n=43), 16 (61.5%) of 26 had had an MMR 
by 24 months. In group II, consisting of patients 
with previously diagnosed CML (n=56), 14 (58.3%) 
of 24 had had an MMR owing to IM treatment. Of 
the evaluatable patients, 86.1% in group I(n=37) 
and 77.9% in group II(n=31) had had a CCR by 
30 months. These findings are comparable to those 
reported in the IRIS study9）. In summation, the 
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MMR rate was 30% to 70%, and the CMR rate 
7% to 34% for CP-CML patients who underwent 
IM treatment. Patients who have a CMR with IM 
therapy are predicted to form an upward trend17）.
   From January 2002 to September 2006, 7 of the 
16 patients who had a CMR IM was discontinued, 
and then all of them experienced early relapse. 
One reason for stopping IM treatment was adverse 
events, typified by facial edema or itching eruption. 
Such adverse events showed the same tendency in 
previous reports22－24）. Molecular and cytogenetic 
relapses occurred rapidly in all our patients. This 
is partly because the period of molecular remission 
before IM discontinuation was too short (4.3 
months). IM was re-started for all 7 patients at a 
low dose (100-300mg/day). All had a CMR, and 
significantly, one had a 3rd CMR on receiving 
a 100mg/day low dose. This suggests that CML 
patients treated with IM who have a CMR can be 
maintained at that level with a low drug dose. In all 
the reported cases, including ours, patients who re-
started IM responded rapidly, indicative that there 
was no acquired resistance to it 22－25）.
   Other case reports of patients with a CMR 
who stopped IM have been published22－25）. The 
conclusions of those reports are shown in Table 3. 
Twenty-one patients in molecular remission who 
stopped IM have been documented. In 12 relapse 
was rapid. The median period from discontinuation 
of IM to relapse was 4.3 months (range, 1-10 
months), but 9 patients continued to have a CMR. 
The median follow-up time from IM discontinuation 
Table 3.　Recent reports on discontinuation of IM therapy after complete molecular remission.
Patient Age Sex CML status IFN/Responseat IM
Time from CMR
to IM
discontinuation 
(months)
Relapse/Follow-up
time (months)
Rousselot P, et al.; Blood 2007
1 42 F CP +/NR 26 +/3
2 54 M CP +/NR 30 +/2
3 75 F CP +/NR 45 +/1
4 83 F CP +/NR 45 +/2
5 73 M AP +/mCR 42 +/1
6 58 F CP +/NR 27 +/5
7 76 M CP +/NR 32 ‒/+22
8 68 M CP +/NR 44 ‒/+9
9 58 F CP +/NR 24 ‒/+24
10 71 M CP +/pCR 34 ‒/+21
11 66 F CP +/pCR 32 ‒/+15
12 78 M CP +/NR 32 ‒/+9
Merante S, et al.; Haematologica 2005
13 63 M CP +/NR 19 +/7
14 51 F CP +/CCR 17 +/10
15 60 M CP +/NR 13 ‒/+15
16 52 F CP +/NR 14 ‒/+14
Mauro MJ, et al.; Leukemia Res 2004 
17 36 F CP +/NR 8 +/3
18 36 F CP - 8 ‒/+12
Cortes J, et al.; Blood 2004 
19 34 F CP +/NR 12 +/3
20 70 M CP - 12 +/6
21 40 F AP +/NR 18 +/8
IM: imatinib mesylate    CMR: complete molecular response    NR: no response    CCR: complete cytogenetic response
mCR: minor cytogenetic response       pCR: partial cytogenetic response   
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was 15 .7  months (range, 9-24  months).  No 
significant difference was found between relapsing 
and non-relapsing patients. Rousselot et al25）
reported six patients (50%) in persistent molecular 
remission after a median follow-up of 18 months 
(range, 9-24months), and a trend for a shorter time 
to bcr-abl negativity (8.5 months in non-relapsing 
patients versus 11 months in relapsing ones, P=.05). 
Moreover, the relapse rate was lower (50%) in his 
study, as compared with previous studies, because 
the median period of molecular remission before 
IM interruption was longer (32 months; range, 24-
45 months)22－25）. In our study, the cytogenetic and 
molecular responses of Japanese CML patients to 
IM therapy showed equivalent therapeutic effects 
when compared with previous overseas reports. In 
all the reported cases of discontinued IM therapy, 
however, early relapse occured. In addition, the 
median period to relapse (4.9 months) was similar 
to that in previous reports (4.3 months)22－25）.
   To conclude, we found that Japanese CML 
patients treated with IM who were in CMR had 
early relapses once IM therapy was discontinued. 
Therefore, at present it is not recommended to 
discontinue IM treatment for patients who are in 
molecular remission. On the one hand, as reported 
previously25）, patients who stopped receiving 
IM who had been in CMR for more than 2 years 
remained in remission after 18 months of follow 
up. Our study found that 3 patients who received 
100-300mg/day low dose IM had a CMR (Table 2). 
These findings suggest that the discontinuation or 
reduction of IM is beneficial in some instances for 
CMR patients. We need gather more information 
on Japanese CML patients, in order to devise better 
CML treatment strategies for Japanese patients who 
have a CMR with IM.
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